期刊文献+

益赛普治疗类风湿性关节炎疗效观察与分析 被引量:2

暂未订购
导出
摘要 目的回顾我院类风湿性关节炎治疗疗效观察与分析。方法 25例类风湿性关节炎患者分成2组,分别为治疗组与对照组,对照组采用甲氨蝶呤加正清风痛宁缓释片治疗,治疗组采用甲氨蝶呤(MTX)联合益赛普治疗。观察治疗前、第1、4及第8周各项观察指标变化。结果 ACR20、ACR50、ACR70治疗组与对照组相比,治疗组与对照组比较差异有统计学意义(P<0.05)。治疗组与对照组DAS28评分<3.2的百分率相比,治疗组DAS28评分较对照组有明显下降,疾病活动性降低,2组比较具有统计学差异。结论益赛普是一种治疗RA的有效药物,近期能明显缓解临床症状,值得临床推广。
作者 黎艳容
机构地区 娄底市中心医院
出处 《中外医疗》 2012年第1期79-80,共2页 China & Foreign Medical Treatment
  • 相关文献

参考文献7

  • 1陆再英,钟南山,主编.内科学[M].第7版.北京:人民卫生出版社,2008:778-779.
  • 2PREVOO ML,K UPER HH,VANT HOFMA,et al.Modified disease activity scores that include twenty﹣eight﹣joint counts.Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis[J].A rthritis Rheum,1995,38(1):315-324.
  • 3FELDMANN M,BRENNAN FM,FOXWELL BM,et al.The role of TNF alpha and L-1 in rheumatoid arthritis[J].Curr Dir Autoimmun,2001,3:188-199.
  • 4邓小虎,黄烽.英夫利西单抗治疗炎性关节病的研究进展[J].中国药物应用与监测,2006,3(6):10-14. 被引量:17
  • 5CHARLESP,ELLIOTTMJ,DAVISD,et al.Regulation of cytokines,cytokine inhibitors,and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis[J].J Immunol,1999,163(3):1521-1528.
  • 6杨春花,黄烽.英夫利西单抗在风湿性疾病中的应用[J].中国药物应用与监测,2006,3(6):5-10. 被引量:7
  • 7殷彤,陈友光,董振香,刘一.注射用英夫利西单抗[J].中国新药杂志,2009,18(11):978-980. 被引量:13

二级参考文献68

  • 1邓小虎,黄烽.英夫利西单抗治疗炎性关节病的研究进展[J].中国药物应用与监测,2006,3(6):10-14. 被引量:17
  • 2MAIN1 R, ST CLAIR EW, BREEDVELD F, et al. Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase Ⅲ trial [J]. Lancet, 1999,354(9194) :1932 - 1939.
  • 3ST CLAI EW, VAN DER HEIJDE D, SMOLEN J, et al. Combi- nation of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial [ J]. Arthritis Rheum, 2004,50(11 ) :3432 -3443.
  • 4MAINI RN, BREEDVELD FC, KALDEN JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis[ J]. Arthritis Rheum, 1998, 41(9) :1552 - 1563.
  • 5LANGE U, TEICHMANN J, MULLE LADNER U, et at. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-antibody: a prospective open-label pilot study [ J ]. Rheumatology, 2005, 44 ( 12 ) : 1546 - 1548.
  • 6TARGAN SR, HANAUER SB, VAN DEVENTER SJH. A shortterm study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Corhn's disease[JJ. N Engl J Med, 1997,337 (15) :1029 - 1035.
  • 7HANAUER SB, FEAGAN BG, LICHTENSTIN GR,et al. Maintenance infiliximab for Crohn's disease: the ACCENT I randomized trial[J]. Lancet, 2002,359(9317) :1541 -1549.
  • 8PRESENT DH, RUTGEERTS P, TARGAN S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease[ J]. N Engl J Med, 1999,340 ( 18 ) : 1398 - 1405.
  • 9BRAUN J, BRANDT J, LISTING J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial[ J ]. Lancet,2002,359 (9313 ) : 1187 - 1193.
  • 10VAN DEN BOSCH F, KRUITHOF E, BAETEN D, et al. Randomized double-bllnd comparison of chimeric monoclonal antibody to tumor necrosis factor alpha(infliximab) versus placebo in active spondylarthropathy [ J ]. Arthritis Rheum, 2002, 46 ( 3 ) : 755 -765.

共引文献554

同被引文献14

引证文献2

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部